This proposal evaluates the translational potential of optogenetic therapy, an approach whereby visual function is achieved through the use of a molecular prosthesis that transmits its signals to downstream visual circuits. Studies in vitro and in vivo in animal models by our collaborators (and others) have demonstrated that light-activated chloride pumps or channels can be introduced into specific retinal cell types in diseased or atrophic retinas. There, these molecular prostheses can permit visual responses where before, there were none. The present program aims to address the knowledge gaps and technical limitations relevant to development of optogenetic therapy in two different paradigms: 1) Physiologically optimized forms of Halorhodopsin (NpHR) will be used to activate function of failing cone photoreceptors after the rod photoreceptors have degenerated;2) Optimized Channelrhodopsins (ChRd) will be used to confer light responsiveness to second order retinal neurons in degenerated retinas. We will design and develop the appropriate vectors, delivery strategies and outcome measures for each paradigm, will carry out the prerequisite preclinical safety and efficacy studies, and will bring one of the studies (NpHR) to clinical trial. In the process, novel strategies of altering the transduction characteristics of adeno-associated virus (AAV) will be developed, new surgical approaches which could be applied to human eyes will be devised, and sensitive, noninvasive, clinically relevant outcome measures will be defined. Simultaneous with development of the technology, we will evaluate the bioethics of gene therapy-mediated delivery of molecular prostheses in humans. This comprehensive program benefits greatly from the wisdom and experience of many talented collaborators and advisors and takes advantage of the infrastructure that the PI has already developed for ocular gene therapy translational research. Successful application of optogenetic therapy will expa

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
5DP1EY023177-03
Application #
8536302
Study Section
Special Emphasis Panel (ZGM1-NDPA-A (01))
Program Officer
Shen, Grace L
Project Start
2011-09-30
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$774,800
Indirect Cost
$290,550
Name
University of Pennsylvania
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Song, Ji Yun; Aravand, Puya; Nikonov, Sergei et al. (2018) Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital Blindness. Mol Ther 26:1581-1593
Maurer, Anna C; Pacouret, Simon; Cepeda Diaz, Ana Karla et al. (2018) The Assembly-Activating Protein Promotes Stability and Interactions between AAV's Viral Proteins to Nucleate Capsid Assembly. Cell Rep 23:1817-1830
Chung, Daniel C; McCague, Sarah; Yu, Zi-Fan et al. (2018) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol 46:247-259
Russell, Stephen; Bennett, Jean; Wellman, Jennifer A et al. (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849-860
Carvalho, Livia S; Turunen, Heikki T; Wassmer, Sarah J et al. (2017) Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting. Front Neurosci 11:503
Landegger, Lukas D; Pan, Bifeng; Askew, Charles et al. (2017) A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol 35:280-284
Wassmer, Sarah J; Carvalho, Livia S; György, Bence et al. (2017) Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection. Sci Rep 7:45329
Pan, Bifeng; Askew, Charles; Galvin, Alice et al. (2017) Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c. Nat Biotechnol 35:264-272
Ramachandran, Pavitra S; Lee, Vivian; Wei, Zhangyong et al. (2017) Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. Hum Gene Ther 28:154-167
Bennett, Jean (2017) Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. Mol Ther 25:1076-1094

Showing the most recent 10 out of 32 publications